Health

  • March 03, 2026

    Ex-FDA Leaders Rebut Contraception Rollbacks At 3rd Circ.

    Former FDA commissioners argued that Trump-era religious exemptions for birth control coverage jeopardize public health and distort medical science, in an animus brief filed Monday with the Third Circuit.

  • March 03, 2026

    FDA Targets Advertising For Knockoff Weight-Loss Meds

    The U.S. Food and Drug Administration on Tuesday accused about 30 telehealth companies of illegally marketing compounded weight-loss and diabetes drugs, the agency's latest salvo in a crackdown on direct-to-consumer pharmaceutical advertising.

  • March 03, 2026

    NC Doctor's Bid For New Trial Is Too Late, Judge Says

    A North Carolina federal judge has refused to order a new trial for a doctor convicted of participating in an $11 million Medicare fraud scheme, finding that because the motion did not contain new evidence, the deadline to request another trial has passed.

  • March 03, 2026

    Florida Man Pleads Guilty In $24M HIV Drugs Fraud Scheme

    The owner of a marketing company in Florida has pled guilty to receiving kickbacks as part of a $24 million scheme to sign up Medicare and Medicaid beneficiaries for HIV prophylactic medications they did not need.

  • March 03, 2026

    Wells Fargo Escapes Ex-Workers' Prescription Cost Suit

    Former Wells Fargo workers on the employer healthcare plan failed to show that the company violated federal benefits law by allowing them to overpay for prescription drugs, a Minnesota federal judge found Tuesday, tossing the proposed class action.

  • March 03, 2026

    Monthly Merger Review Snapshot

    The U.S. Department of Justice got its antitrust case against Live Nation and Ticketmaster teed up for trial, as a court continues mulling the department's settlement last year in a case challenging a deal by Hewlett Packard Enterprise, and lawmakers call for scrutiny of Paramount Skydance's blockbuster acquisition of Warner Bros. Discovery.

  • March 03, 2026

    States Can't Duck Regeneron Counterclaims In FCA Case

    Eleven states pursuing a False Claims Act case against Regeneron Pharmaceuticals over what they say were inflated reimbursements for an eye drug can't block counterclaims by the drugmaker on sovereign immunity grounds, a Massachusetts federal judge has ruled.

  • March 03, 2026

    4th Circ. Won't Revive Retired Miners' Health Fight

    The Fourth Circuit refused Tuesday to reopen a dispute over lifetime retirement health and life insurance benefits from a proposed class of retired coal miners, keeping in place a West Virginia federal court's judgment that broadly favored the company following a seven-day bench trial.

  • March 03, 2026

    Curaleaf Says No Private Info Leaked In Buyers' Data Suit

    Curaleaf Inc. is asking a Florida federal court to throw out a suit alleging that its website failed to protect buyers' personal and health information, saying none of the information the site or its software collects is personal property or healthcare information.

  • March 03, 2026

    Judge Won't Rely On DOJ 'Decency' In Trans Records Case

    A Pennsylvania federal judge blocked the U.S. Department of Justice from getting patient-specific records of gender-affirming care at the University of Pittsburgh Medical Center Children's Hospital, excoriating the government's request and its reasoning for demanding the data.

  • March 03, 2026

    1st Circ. Won't Revive Boston's Opioid Claims Against PBMs

    Boston lost its bid to revive opioid crisis-related claims against two pharmacy benefit managers, as a First Circuit panel affirmed that the suit came years too late.

  • March 03, 2026

    FTC Makes 'Significant Progress' In OptumRx, Caremark Talks

    Federal Trade Commission staffers got more time Tuesday for settlement talks with OptumRx and Caremark that could end the agency's case accusing the pharmacy benefit managers of inflating insulin prices, with staffers citing considerable progress in the weeks since inking a deal with Express Scripts.

  • March 03, 2026

    Fla. Billing Co. To Settle With Feds Over $15M Medicare Fraud

    The U.S. government has settled its False Claims Act lawsuit with a medical coding and billing business it accused of aiding a Miami-based laboratory in fraudulently billing Medicare for more than $15 million in genetic tests.

  • March 02, 2026

    High Court Blocks California's Gender Privacy Rule

    The U.S. Supreme Court on Monday reinstated a lower court order that barred California public schools from allowing transgender and gender-nonconforming students to use different names and pronouns at school without their parents' knowledge or consent while the order is appealed.

  • March 02, 2026

    E-Rate Could Cut Some Regulatory Fat, FCC Told

    While the Federal Communications Commission is looking for regulations to get rid of, one organization said it has a list of options for the agency to consider when it comes to the E-Rate subsidy program.

  • March 02, 2026

    Texas AG Says Gender Care Ban Includes Mental Health

    Mental-health professionals in Texas risk losing their licenses and public funding if they "facilitate" the gender-affirming care banned under state law, said an opinion issued Friday by Attorney General Ken Paxton, which calls them the "gatekeepers."

  • March 02, 2026

    Abbott Beats Data Sharing Suit Over Glucose Tracking Trial

    An Illinois federal judge on Monday permanently tossed a lawsuit accusing Abbott Laboratories of unlawfully sharing website visitors' personal data with Meta and Google, saying the plaintiffs can't plausibly show that their legally protected information ever left Abbott's website.

  • March 02, 2026

    Epic Must Face Price Conspiracy Claims Over Gallstone Drug

    Epic Pharma LLC must face the majority of suits by hospitals, insurers and other drug purchasers alleging it conspired to raise and control the price of gallstone medication ursodiol, a Pennsylvania federal judge ruled Monday.

  • March 02, 2026

    3rd Circ. Unsure Criticism Of Prof's DEI Stance Is Defamation

    A Third Circuit panel on Monday questioned whether the retraction of a former University of Pittsburgh program director's article criticizing diversity, equity and inclusion was a purely academic debate the courts should avoid, or if statements that it "misrepresented" facts were enough to sustain defamation claims.

  • March 02, 2026

    SEC Inks $200K Settlement In False PPE Press Release Suit

    The CEO and consultant of a consumer goods company will pay over $200,000 to settle the U.S. Securities and Exchange Commission's claims that they artificially inflated the company's share price by nearly 200% by disseminating a false press release at the beginning of the COVID-19 pandemic.

  • March 02, 2026

    Anthem Avoids Patients' Ghost Network Suit In NY

    A New York federal judge on Monday granted Anthem escape from a proposed class action from patients who alleged inaccuracies in the insurer's mental health provider directory violated New York state laws, holding their claims were preempted by federal employee health benefits law.

  • March 02, 2026

    NC Care Co. Operator Urges Judge To Ax Wage Verdict

    A North Carolina residential mental health company and its owner have urged a federal judge to nix a jury verdict finding that they underpaid workers, saying the employees relied on speculative evidence and a damages summary that was disclosed too late.

  • March 02, 2026

    6th Circ. Upholds 12-Year Stint For Mich. Doc In 'Pill Mill' Case

    The Sixth Circuit affirmed the convictions and 12-year prison sentence of a Michigan doctor accused of operating a cash-only "pill mill" that wrote thousands of opioid prescriptions, holding that the trial judge properly handled the jury instructions and key evidentiary rulings.

  • March 02, 2026

    Hagens Berman Denied Rehearing Bid In Sanctions Dispute

    The Third Circuit on Monday rejected plaintiffs firm Hagens Berman Sobol Shapiro LLP's request to reconsider weighing in on the sanctions dispute in a since-dropped product liability case that resulted in the trial court judge referring the firm for possible criminal investigation.

  • March 02, 2026

    Gyre, Cullgen Merge In $300M All-Stock Deal

    Commercial-stage biopharmaceutical company Gyre Therapeutics Inc. on Monday announced plans to acquire clinical-stage biopharmaceutical company Cullgen Inc. in an all-stock deal valued at roughly $300 million.

Expert Analysis

  • 5 Years In, COVID-19 Fraud Enforcement Landscape Is Shifting

    Author Photo

    As the government moves pandemic fraud enforcement from small-dollar individual prosecutions to high-value corporate cases, and billions of dollars remain unaccounted for, companies and defense attorneys must take steps now to prepare for the next five years of scrutiny, says attorney David Tarras.

  • Vanda Ruling Opens Door For Contesting FDA Drug Denials

    Author Photo

    The D.C. Circuit's recent decision in Vanda Pharmaceuticals v. U.S. Food and Drug Administration creates new opportunities and considerations for drug companies navigating the FDA approval process, establishing that litigation is an option when the FDA refuses to hold a hearing, say attorneys at Polsinelli.

  • Series

    Law School's Missed Lessons: Mastering Time Management

    Author Photo

    Law students typically have weeks or months to prepare for any given deadline, but the unpredictability of practicing in the real world means that lawyers must become time-management pros, ready to adapt to scheduling conflicts and unexpected assignments at any given moment, says David Thomas at Honigman.

  • Courts Keep Upping Standing Ante In ERISA Healthcare Suits

    Author Photo

    As Article III standing becomes increasingly important in litigation brought by employer-sponsored health plan members under the Employee Retirement Income Security Act, several recent cases suggest that courts are taking a more scrutinizing approach to the standing inquiry in both class actions and individual matters, say attorneys at Crowell & Moring.

  • Calif. Bill May Shake Up Healthcare Investment Landscape

    Author Photo

    If signed by the governor, newly passed California legislation would significantly expand the Office of Health Care Affordability's oversight of private equity and hedge fund investments in healthcare companies and management services organizations, and raise several questions about companies' data confidentiality and filing burdens, say attorneys at Ropes & Gray.

  • How Hyperlinks Are Changing E-Discovery Responsibilities

    Author Photo

    A recent e-discovery dispute over hyperlinked data in Hubbard v. Crow shows how courts have increasingly broadened the definition of control to account for cloud-based evidence, and why organizations must rethink preservation practices to avoid spoliation risks, says Bree Murphy at Exterro.

  • Pharma Copay Programs Raise Complex Economic Questions

    Author Photo

    The growing prevalence of copay accumulator and maximizer programs in the pharmaceutical industry is drawing increased scrutiny from patients, advocacy groups, lawmakers and courts, bringing complex questions about how financial responsibility for prescription drug purchases is determined and complicating damages assessments in litigation, say analysts at Analysis Group.

  • State False Claims Acts Can Help Curb Opioid Fund Fraud

    Author Photo

    State versions of the federal False Claims Act can play an important role in policing the misuse of opioid settlement funds, taking a cue from the U.S. Department of Justice’s handling of federal fraud cases involving pandemic relief funds, says Kenneth Levine at Stone & Magnanini.

  • 'Occurrence' Lessons From Policyholder's COVID Ruling Win

    Author Photo

    The Minnesota Court of Appeals recently handed policyholders an important win in Life Time v. Zurich American Insurance, reversing a trial court ruling that had capped coverage under a communicable disease endorsement at a single occurrence, showing the importance of fact-specific inquiry, say attorneys at Hunton.

  • Series

    Writing Musicals Makes Me A Better Lawyer

    Author Photo

    My experiences with writing musicals and practicing law have shown that the building blocks for both endeavors are one and the same, because drama is necessary for the law to exist, says Addison O’Donnell at LOIS Law.

  • Series

    Adapting To Private Practice: From Va. AUSA To Mid-Law

    Author Photo

    Returning to the firm where I began my career after seven years as an assistant U.S. attorney in Virginia has been complex, nuanced and rewarding, and I’ve learned that the pursuit of justice remains the constant, even as the mindset and client change, says Kristin Johnson at Woods Rogers.

  • Transmission Security Has A Critical Role In Healthcare

    Author Photo

    In light of the U.S. Department of Health and Human Services' Office of Civil Rights' continuing enforcement initiative focusing on businesses' accurate and thorough security risk assessments under the Health Insurance Portability and Accountability Act, covered entities should not neglect the importance of transmission security, says John Howard at Clark Hill.

  • Rebutting Price Impact In Securities Class Actions

    Author Photo

    Defendants litigating securities cases historically faced long odds in defeating class certification, but that paradigm has recently begun to shift, with recent cases ushering in a more searching analysis of price impact and changing the evidence courts can consider at the class certification stage, say attorneys at Katten.

  • 7 Document Review Concepts New Attorneys Need To Know

    Author Photo

    For new associates joining firms this fall, stepping into the world of e-discovery can feel like learning a new language, but understanding a handful of fundamentals — from coding layouts to metadata — can help attorneys become fluent in document review, says Ann Motl at Bowman and Brooke.

  • FTC Actions Highlight New Noncompete Enforcement Strategy

    Author Photo

    Several recent noncompete-related actions from the Federal Trade Commission — including its recent dismissal of cases appealing the vacatur of a Biden-era noncompete ban — reflect the commission's shift toward case-by-case enforcement, while confirming that the agency intends to remain active in policing such agreements, say attorneys at Debevoise.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Health archive.